The US Food and Drug Administration’s review of Esteve Pharmaceuticals' fixed-dose combination of tramadol and celecoxib shows how the agency intends to apply a recent draft guidance calling attention to the comparative benefits and risks of new opioid products relative to existing analgesics.
In a briefing document released ahead of a 15 January meeting of the anesthetic and analgesic drug products and...





